<qa>  To determine the overall response rate and complete response rate of venetoclax in combination withI. To determine the overall response rate ORR and complete response rate CR of venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsedrefractory or previously untreated patients with CLL. 